IL17A and Alzheimer disease: This was evidenced by decreased levels of Abeta1-42, GFAP, S100 proteins, and myeloperoxidases (MPOs) [167], underscoring the potential collaborative role of IL-17 and its associated cytokines in exacerbating neuroinflammation and neurodegeneration in AD [168].